Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC50 in healthy adults and mild to moderate plaque psoriasis
NCT07024602Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASC50 in plaque psoriasis (7 cohorts), sponsored by Ascletis Pharma Inc. Primary endpoint: Adverse Events at Day 43. Started Jun 2025; status: completed.
02
Drugs
ASC50
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07024602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024602.